Baricitinib completely inhibits the JAK-STAT (signal transducer and activator of transcription) signaling pathway, thereby inhibiting targeted cytokines (e.g., TNF-α, IL-17, and IL-23), which could be a potential explanation for baricitinib treatment of ACH (53). Here, IL23A is linked to achondroplasia.